(-)-gallocatechin gallate has been researched along with fingolimod in 1 studies
| Studies ((-)-gallocatechin gallate) | Trials ((-)-gallocatechin gallate) | Recent Studies (post-2010) ((-)-gallocatechin gallate) | Studies (fingolimod) | Trials (fingolimod) | Recent Studies (post-2010) (fingolimod) |
|---|---|---|---|---|---|
| 19 | 0 | 10 | 65 | 0 | 51 |
| Protein | Taxonomy | (-)-gallocatechin gallate (IC50) | fingolimod (IC50) |
|---|---|---|---|
| Sphingosine 1-phosphate receptor 1 | Homo sapiens (human) | 0.7219 | |
| Sphingosine 1-phosphate receptor 5 | Homo sapiens (human) | 2.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Araldi, GL; Hwang, YW | 1 |
1 other study(ies) available for (-)-gallocatechin gallate and fingolimod
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of polyphenol derivatives as DYRK1A inhibitors. The discovery of a potentially promising treatment for Multiple Sclerosis.
Topics: Catechin; Humans; Multiple Sclerosis; Phosphorylation; Polyphenols; Structure-Activity Relationship; Tea | 2022 |